Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA

Watchlist Manager
Sun Pharmaceutical Industries Ltd Logo
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Watchlist
Price: 1 814.6 INR 0.32% Market Closed
Market Cap: 4.4T INR
Have any thoughts about
Sun Pharmaceutical Industries Ltd?
Write Note

Sun Pharmaceutical Industries Ltd
Income to Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sun Pharmaceutical Industries Ltd
Income to Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income to Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Income to Minority Interest
-â‚ą630.1m
CAGR 3-Years
-96%
CAGR 5-Years
34%
CAGR 10-Years
22%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Income to Minority Interest
-â‚ą862m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Income to Minority Interest
-â‚ą56.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
16%
Lupin Ltd
NSE:LUPIN
Income to Minority Interest
-â‚ą255m
CAGR 3-Years
-17%
CAGR 5-Years
-22%
CAGR 10-Years
2%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Income to Minority Interest
â‚ą0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Income to Minority Interest
-â‚ą288.8m
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sun Pharmaceutical Industries Ltd
Glance View

Market Cap
4.4T INR
Industry
Pharmaceuticals
Economic Moat
Narrow

Sun Pharmaceutical Industries Ltd. began its journey in 1983 with a vision to provide quality healthcare to billions worldwide. Originating from India, Sun Pharma has steadily emerged as a global leader in the pharmaceutical industry. The company’s strength stems from its ability to efficiently manufacture, develop, and market a wide range of generic pharmaceuticals and therapeutic formulations. With a significant footprint in over 100 countries, it is driven by a robust pipeline of drugs encompassing key therapeutic areas such as psychiatry, cardiology, neurology, and gastroenterology. A hallmark of Sun Pharma’s strategy has been its strong focus on research and development, specifically in creating affordable medicines that tackle complex medical conditions. The company’s business model revolves around a dual strategy: the development of complex generics and innovative specialty products. This approach allows Sun Pharma to capitalize on both the high-volume, cost-efficient production of off-patent drugs and the value-driven, specialized therapy segments. By leveraging its R&D capabilities, the company explores new drug delivery systems and complex formulations, which not only ensure a steady flow of new product introductions but also enhance its competitive edge in the market. This blend of innovation and scale positions Sun Pharmaceutical Industries Ltd. as a dynamic force in the global pharmaceutical landscape, continually navigating the intricate balance of providing both profitable growth and accessible healthcare solutions.

SUNPHARMA Intrinsic Value
1 068.6 INR
Overvaluation 41%
Intrinsic Value
Price

See Also

What is Sun Pharmaceutical Industries Ltd's Income to Minority Interest?
Income to Minority Interest
-630.1m INR

Based on the financial report for Sep 30, 2024, Sun Pharmaceutical Industries Ltd's Income to Minority Interest amounts to -630.1m INR.

What is Sun Pharmaceutical Industries Ltd's Income to Minority Interest growth rate?
Income to Minority Interest CAGR 10Y
22%

Over the last year, the Income to Minority Interest growth was -973%. The average annual Income to Minority Interest growth rates for Sun Pharmaceutical Industries Ltd have been -96% over the past three years , 34% over the past five years , and 22% over the past ten years .

Back to Top